Variation in Sulphonylurea Response in Type 2 Diabetes
Status:
Terminated
Trial end date:
2011-03-03
Target enrollment:
Participant gender:
Summary
The study hypothesis is that people who respond well to sulphonylureas have a different
underlying cause for their diabetes than people who respond poorly to this medication. We are
using two approaches to study this. In one approach we look at people who have previously
responded well or poorly, confirm this by rechallenging them with a sulphonylurea drug, and
then looking at how well they produce insulin in response to glucose and an intravenous
sulphonylurea called tolbutamide. The second approach identifies people with a certain
genetic predisposition to diabetes (due to changes in the TCF7L2 gene) and then looks at how
well they respond to sulphonylurea medication.